Overview

Tolerability and Safety of HF158K1 Injection in Participants With HER-2 Positive or Low Expression Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-12-22
Target enrollment:
Participant gender:
Summary
HF158K1 is a modified targeted doxorubicin liposome injection for the treatment of HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors. HF158K1 was developed and optimized based on Doxil, aiming to further improve antitumor efficacy while reducing adverse effects.
Phase:
Phase 1
Details
Lead Sponsor:
HighField Biopharmaceuticals Corporation